Estados Unidos · Agencias y tiempo real · PR Newswire

ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis

Publicado por PR Newswire · Estados Unidos hace 1 h

IL-23 inhibitor approved exclusively for healthcare provider-administered treatment Expands use of ILUMYA beyond moderate-to-severe plaque psoriasis strengthening Sun Pharma's…

Leer el artículo completo en PR Newswire Inicie sesión para guardar

MarketNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.prnewswire.com)

ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis

También te puede interesar

What to consider if a company that made AI-related job cuts wants you back

Roblox Reports Third Quarter 2026 Financial Results

Takeaways from the Inaugural Dow Jones Energy Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows

ILUMYA® (tildrakizumab-asmn) approved in the U.S. for the Treatment of Adults with Active Psoriatic Arthritis

Compartir

También te puede interesar

What to consider if a company that made AI-related job cuts wants you back

Roblox Reports Third Quarter 2026 Financial Results

Takeaways from the Inaugural Dow Jones Energy Forum

MT Newswires' MCP Server Now Available in Perplexity Computer, Bringing Real-Time Global Market News to AI-Driven Workflows